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CYP2C8 Status of Patients
With Malaria Inﬂuences
Selection of Plasmodium
falciparum pfmdr1 Alleles
After Amodiaquine-
Artesunate Treatment
TO THE EDITOR—We have read with great
interest the article by Paganotti et al [1], in
which evidence is presented about the
possible inﬂuence of human pharmacoge-
netics on the development of chloroquine
(CQ) resistance by Plasmodium falcipa-
rum. This prompted us to hypothesize
that such inﬂuence would be more visible
and signiﬁcant when considering the
structurally related amodiaquine (AQ). In
fact, although CYP2C8 is a secondary
player in the metabolism of CQ [2], it is
essential for the cytochrome P450 (CYP)
associated biotransformation of AQ to its
therapeutically main active metabolite, de-
sethylamodiaquine (DEAQ) [3].
The in vivo parasite response to AQ
therapy is modulated by polymorphisms
in the P. falciparum multidrug resistance
1 gene (pfmdr1), particularly those con-
cerning the N86Y [4], Y184F, and D1246Y
[5, 6] single-nucleotide polymorphisms
(SNPs). Accordingly, we hypothesized
that the CYP2C8 status of the target
population would inﬂuence the inten-
sity of posttreatment selection of these
polymorphisms. Such events should be
reﬂected in signiﬁcant differences in
the frequencies of these SNPs between
parasites recurrently infecting patients
carrying wild-type CYP2C8*1/*1 and
those infecting subjects harboring mi-
nor CYP2C8 alleles coding for activity-
compromised enzymes. In this context,
the Zanzibari population offers the ad-
vantage of being an African native pop-
ulation with very high prevalence of the
CYP2C8*3 allele, which codes for a very-
low-activity enzyme [7].
We retrospectively analyzed the
CYP2C8 status of patients experiencing
recurrent parasitemia in 2 similar trials
on the efﬁcacy of ASAQ for uncompli-
cated P. falciparum malaria [5, 8]. Both
trials had a 42-day follow-up period and
were performed at a time when malaria
transmission was still high in Zanzibar.
The CYP2C8*2 and 2C8*3 alleles were
characterized using previously published
PCR-RFLP methods [7]. The statistical
analysis was done using the 2-tailed
Fisher exact test (GraphPad QuickCalcs;
available at: http://www.graphpad.com).
In total, 116 patients (age, <5 years)
were analyzed for the main CYP2C8
polymorphisms. These pharmacogenet-
ics results were merged with previously
published parasite genotype data on the
pfmdr1 N86Y, Y184F, and D1246Y
SNPs [5, 8].
Here, we adopted an extreme discord-
ant group analysis [9] through the com-
parison of a group of carriers with the
2C8*3 allele, known to code for the signif-
icantly impaired enzyme encoded by
CYP2C8*3, with a group carrying the *1/
*1 haplotype, which encode the fully
functional enzyme. Carriers of CYP2C8*3
had an increased frequency of infections
harboring the pfmdr1 86Y in pure form
(100% vs 74.6%; P < .05) and 1246Y
(46.7% vs 13.6%; P < .01) alleles, com-
pared with the reference homozygous
wild-type group (Figure 1). The low level
of polymorphisms at position 184 pre-
cluded a meaningful statistical analysis of
this SNP in isolation.
The 86Y/184Y/1246Y haplotype is
selected in vivo after AQ and ASAQ expo-
sure [4–6]. For 105 of the analyzed infec-
tions, the complete parasite haplotype
analysis was available. Consistent with
the pattern observed with the individual
SNPs, carriage of YYY-carrying parasites
(ie, YYY, MYY, YMY, and YYM) tended
to be more frequent among the 2C8*3
carriers, compared with the wild type
Figure 1. Frequency of the carriers of 2C8*1/*1 and of one *3 allele among the different para-
site pfmdr1 SNPs/haplotypes. # YYY carrying infections, ie, including not only the pure, but also the
MYY, YMY, YYM haplotype was considered. *p < 0.05; **p < 0.01; ***near signiﬁcant trend,
p = .056.
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group (53.3% vs 24.6%; P = .056). After
exclusion of parasites with the SNP at
position 184, we observed that the pure
haplotype 86Y/1246Y was more frequent
among parasites in the 2C8*3 carriers
(46.7% vs 10.7%; P < .01), suggesting
the importance of these 2 SNPs and a
minor role for the SNP at position 184
in this host pharmacogenetics/pathogen
interaction.
In contrast with the observed with the
2C8*3 carrier subset, carriers of the rela-
tively frequent homozygous 2C8*2/*2
haplotype, as well as the overall subset of
2C8*2 carriers, were not associated with
any of the pfmdr1 SNPs analyzed or the
YYY and YY haplotypes.
The present data only allow a prelimi-
narily discussion about the potential
reasons for the observed frequency trends.
The metabolism of AQ is complex, with
several pathways expected to operate in
parallel with the main AQ-to-DEAQ route
[10]. It is conceivable that carriers of the
CYP2C8*3 allele allow a longer AQ half-
life. As a consequence, it is possible that a
nonnegligible fraction of the AQ pool is
deviated toward secondary metabolic
pathways, leading to a decreased DEAQ
exposure. This will particularly beneﬁt
parasites already prone to be tolerant to
DEAQ, such as 86Y/1246Y haplotype car-
riers, which will be more readily selected.
In conclusion, consistent with the
study by Paganotti et al [1], our work
supports a potential inﬂuence of the
host pharmacogenetic makeup on the
long-term selection of parasite charac-
teristics associated with antimalarial drug
response. The precise nature of such
pharmacogenetic-driven host-pathogen
interactions is probably complex, but it is
worth further explorations with speciﬁcally
designed studies.
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